Mariagrazia Rullo

Dr. Mariagrazia Rullo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MRMariagrazia Rullo
Mariagrazia Rullo
MCMarco Cipolloni
Marco Cipolloni
MCMarco Catto
Marco Catto
CCCarolina Colliva
Carolina Colliva
Daniela Valeria MinieroDaniela Valeria Miniero
Daniela Valeria Miniero
Leonardo PisaniLeonardo Pisani
Leonardo Pisani

29 August 2018 in Molecules
Verified
Journal Article
Open access
PDF file
LPLuca Piemontese
Luca Piemontese
GVGabriele Vitucci
Gabriele Vitucci
MCMarco Catto
Marco Catto
ALAntonio Laghezza
Antonio Laghezza
FPFilippo Perna
Filippo Perna
MSMichele Solfrizzo
Michele Solfrizzo
A few symptomatic drugs are currently available for Alzheimer’s Disease (AD) therapy, but these molecules are only able to temporary improve the cognitive capacity of the patients if administered in the first stages of the pathology. Recently, important advances have been achieved about the knowledge of this complex condition, which is now considered a multi-factorial disease. Researchers are, thus, more oriented toward the preparation of molecules being able to contemporaneously act on different pathological features. To date, the inhibition of acetylcholinesterase (AChE) and of β-amyloid (Aβ) aggregation as well as the antioxidant activity and the removal and/or redistribution of metal ions at the level of the nervous system are the most common investigated targets for the treatment of AD. Since many natural compounds show multiple biological properties, a series of secondary metabolites of plants or fungi with suitable structural characteristics have been selected and assayed in order to evaluate their potential role in the preparation of multi-target agents. Out of six compounds evaluated, 1 showed the best activity as an antioxidant (EC50 = 2.6 ± 0.2 μmol/µmol of DPPH) while compound 2 proved to be effective in the inhibition of AChE (IC50 = 6.86 ± 0.67 μM) and Aβ1–40 aggregation (IC50 = 74 ± 1 μM). Furthermore, compound 6 inhibited BChE (IC50 = 1.75 ± 0.59 μM) with a good selectivity toward AChE (IC50 = 86.0 ± 15.0 μM). Moreover, preliminary tests on metal chelation suggested a possible interaction between compounds 1, 3 and 4 and copper (II). Molecules with the best multi-target profiles will be used as starting hit compounds to appropriately address future studies of Structure-Activity Relationships (SARs).

9 December 2019 in Molecules
Verified
Journal Article
Open access
PDF file
MRMariagrazia Rullo
Mariagrazia Rullo
MCMarco Catto
Marco Catto
Antonio CarrieriAntonio Carrieri
Antonio Carrieri
Modesto de CandiaModesto de Candia
Modesto de Candia
Cosimo D. AltomareCosimo D. Altomare
Cosimo D. Altomare
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
A series of 4-aminomethyl-7-benzyloxy-2H-chromen-2-ones was investigated with the aim of identifying multiple inhibitors of cholinesterases (acetyl- and butyryl-, AChE and BChE) and monoamine oxidase B (MAO B) as potential anti-Alzheimer molecules. Starting from a previously reported potent MAO B inhibitor (3), we studied single-point modifications at the benzyloxy or at the basic moiety. The in vitro screening highlighted triple-acting compounds (6, 8, 9, 16, 20) showing nanomolar and selective MAO B inhibition along with IC50 against ChEs at the low micromolar level. Enzyme kinetics analysis toward AChE and docking simulations on the target enzymes were run in order to get insight into the mechanism of action and plausible binding modes.

27 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Rosa PurgatorioRosa Purgatorio
Rosa Purgatorio
Nicola GambacortaNicola Gambacorta
Nicola Gambacorta
Modesto de CandiaModesto de Candia
Modesto de Candia
MCMarco Catto
Marco Catto
MRMariagrazia Rullo
Mariagrazia Rullo
Cosimo D. AltomareCosimo D. Altomare
Cosimo D. Altomare
Recently, the direct thrombin (thr) inhibitor dabigatran has proven to be beneficial in animal models of Alzheimer’s disease (AD). Aiming at discovering novel multimodal agents addressing thr and AD-related targets, a selection of previously and newly synthesized potent thr and factor Xa (fXa) inhibitors were virtually screened by the Multi-fingerprint Similarity Searching aLgorithm (MuSSeL) web server. The N-phenyl-1-(pyridin-4-yl)piperidine-4-carboxamide derivative 1, which has already been experimentally shown to inhibit thr with a Ki value of 6 nM, has been flagged by a new, upcoming release of MuSSeL as a binder of cholinesterase (ChE) isoforms (acetyl- and butyrylcholinesterase, AChE and BChE), as well as thr, fXa, and other enzymes and receptors. Interestingly, the inhibition potency of 1 was predicted by the MuSSeL platform to fall within the low-to-submicromolar range and this was confirmed by experimental Ki values, which were found equal to 0.058 and 6.95 μM for eeAChE and eqBChE, respectively. Thirty analogs of 1 were then assayed as inhibitors of thr, fXa, AChE, and BChE to increase our knowledge of their structure-activity relationships, while the molecular determinants responsible for the multiple activities towards the target enzymes were rationally investigated by molecular cross-docking screening.

1 June 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MPMarco Paolino
Marco Paolino
MRMariagrazia Rullo
Mariagrazia Rullo
Samuele MaramaiSamuele Maramai
Samuele Maramai
MCModesto de Candia
Modesto de Candia
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
CACosimo D. Altomare
Cosimo D. Altomare
Neurodegenerative diseases are multifactorial disorders characterized by protein misfolding, oxidative stress, and neuroinflammation, finally resulting in neuronal loss and cognitive dysfunctions. Nowadays, an attractive strategy to improve the classical treatments is the development of multitarget-directed molecules able to synergistically interact with different enzymes and/or receptors. In addition, an interesting tool to refine personalized therapies may arise from the use of bioactive species able to modify their activity as a result of light irradiation. To this aim, we designed and synthesized a small library of cinnamic acid-inspired isomeric compounds with light modulated activity able to inhibit acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), with remarkable selectivity over butyrylcholinesterase (BChE) and MAO-A, which have been investigated as the enzyme targets related to Alzheimer's disease (AD). The inhibitory activities were evaluated for the pure E-diastereomers and the E/Z-diastereomer mixtures, obtained upon UV irradiation. Molecular docking studies were carried out to rationalize the differences in the inhibition potency of the E and Z diastereomers of the best performing analogue 1c. Our preliminary findings may open-up the way for developing innovative multitarget photo-switch drugs against neurodegenerative diseases.

14 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MRMariagrazia Rullo
Mariagrazia Rullo
GSGabriella La Spada
Gabriella La Spada
ASAngela Stefanachi
Angela Stefanachi
Eleonora MacchiaEleonora Macchia
Eleonora Macchia
Leonardo PisaniLeonardo Pisani
Leonardo Pisani
FLFrancesco Leonetti
Francesco Leonetti
Alzheimer’s disease (AD) causes a great socioeconomic burden because of its increasing prevalence and the lack of effective therapies. The multifactorial nature of AD prompts researchers to search for new strategies for discovering disease-modifying therapeutics. To this extent, the multitarget approach holds the potential of synergic or cooperative activities arising from compounds that are properly designed to address two or more pathogenetic mechanisms. As a privileged and nature-friendly scaffold, coumarin has successfully been enrolled as the heterocyclic core in the design of multipotent anti-Alzheimer’s agents. Herein, we comprehensively summarize the most recent literature (2018–2023), covering the rational design and the discovery of coumarin-containing multitarget directed ligands (MTDLs) whose anti-AD profile encompassed at least two different biological activities relevant for disease onset and progression. To enhance the clarity of presentation, synthetic coumarin-based MTDLs are categorized into four clusters based on their substitution pattern and reported bioactivities: (i) mono-, (ii) di-, and (iii) polysubstituted coumarins directed at protein targets, and (iv) coumarins directed at protein targets with additional metal-chelating features. Before discussing multimodal coumarins, the rationale for addressing each biological target is briefly presented.